Milestone for Stereotaxis' Niobe ES - Analyst Blog

By
A A A

Medical equipment maker Stereotaxis Inc. ( STXS ) reported encouraging results from its recently completed first 50 clinical procedures performed using its new Niobe ES system for treating patients with complex cardiac arrhythmias (a disorder of the heart rhythm). The majority of these procedures were performed to treat atrial fibrillation, the most prevalent form of cardiac arrhythmia.

Results from these procedures, performed in Europe, showed that average time for completion of mapping and ablation for the initial atrial fibrillation patients was 69 minutes.

The Niobe ES system is a part of the company's Epoch platform, which is designed for the electrophysiology ("EP") labs. Introduced in April 2011, Epoch is a comprehensive solution for EP labs and is geared to improve efficiency of cardiac procedures and increase workflow by enabling physicians to control procedures remotely.

The Epoch platform integrates the benefits of remote magnetic catheter control, the efficiency of remote robotic device manipulation and the Vdrive mechanical robotic platform, allowing highly sophisticated procedural data integration and transmission. The Epoch solution is expected to considerably cut procedure time for all types of robotic-assisted EP procedures including atrial fibrillation ablation procedures.

Stereotaxis commenced initial shipment of the Epoch platform in December 2011. The shipments include six system upgrade to the Epoch platform from the company's Niobe II magnetic navigation system for clients across the U.S. and Europe. Based on the positive outcome of the initial clinical procedures, Stereotaxis plans to install 12 additional system upgrades to Niobe ES over the next few months.

Missouri-based Stereotaxis develops and markets advanced cardiology instrument control system for use in cardiac catheterization labs for the treatment of coronary artery disease and arrhythmias.

Stereotaxis offers the Niobe Magnetic Navigation System, which allows physicians to perform complex interventional procedures. Moreover, its Odyssey Enterprise Solution integrates and records all lab data allowing physicians to focus on the patient for optimal procedure efficiency. The company's competitors include Boston Scientific ( BSX ) and Edwards Lifesciences ( EW ).


 
BOSTON SCIENTIF ( BSX ): Free Stock Analysis Report
 
EDWARDS LIFESCI ( EW ): Free Stock Analysis Report
 
STEREOTAXIS INC ( STXS ): Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Business , Stocks

Referenced Stocks: BSX , EW , STXS

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Stocks

Referenced

88%
100%
80%

Most Active by Volume

91,252,153
  • $13.78 ▼ 4.31%
68,133,496
  • $12.93 ▲ 6.77%
57,268,074
  • $46.13 ▲ 2.47%
43,432,023
  • $105.22 ▲ 0.37%
40,880,685
  • $13.46 ▲ 8.90%
40,712,405
  • $98.62 ▲ 0.82%
39,776,976
  • $16.72 ▲ 0.72%
34,688,871
  • $11.16 ▲ 3.05%
As of 10/24/2014, 04:15 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com